cis-2-tert.-Butylcyclohexancarbonsaeure | 27392-15-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: cis-2-tert.-Butylcyclohexancarbonsaeure
• 英文别名: 2alpha-(1,1-Dimethylethyl)-1alpha-cyclohexanecarboxylic acid；(1S,2R)-2-tert-butylcyclohexane-1-carboxylic acid
• CAS: 27392-15-0
• 化学式: C₁₁H₂₀O₂
• 分子量: 184.279
• InChiKey: FVPFFBYHXHQMCY-DTWKUNHWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-tert-butylbenzoic acid 在 platinum on activated charcoal 氢气 作用下， 以 溶剂黄146 为溶剂， 生成 cis-2-tert.-Butylcyclohexancarbonsaeure
  参考文献：
  名称：

  van Bekkum,H. et al., Recueil des Travaux Chimiques des Pays-Bas, 1970, vol. 89, p. 521 - 534

  摘要：

  DOI：

文献信息

• Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof
  申请人：Unoki Gen

  公开号：US20070173519A1

  公开（公告）日：2007-07-26

  A pyrazolopyrimidine derivative represented by formula (1) and pharmaceutically acceptable salt thereof exhibit excellent inhibitory activity against MAPKAP-K2. Accordingly, medicines containing this compound as an active ingredient are expected to be effective for treating diseases mediated by MAPKAP-K2 such as, for example, inflammatory disorder, autoimmune diseases, destructive osteopathy, cancer and/or tumor growth.

  由式（1）表示的吡唑吡嘧啶衍生物及其药用盐对MAPKAP-K2表现出优异的抑制活性。因此，含有该化合物作为活性成分的药物预计对治疗由MAPKAP-K2介导的疾病，如炎症性疾病、自身免疫疾病、破坏性骨病、癌症和/或肿瘤生长等方面具有有效性。
• QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
  申请人：Beshore Douglas C.

  公开号：US20120196845A1

  公开（公告）日：2012-08-02

  The present invention is directed to quinolinone-pyrazolone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及公式（I）的喹啉酮-吡唑酮化合物，它们是M1受体正向变构调节剂，可用于治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。本发明还涉及包括上述化合物的制药组合物，以及在治疗M1受体介导的疾病中使用上述化合物和组合物的方法。
• PYRAZOLOPYRIMIDINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
  申请人：Teijin Pharma Limited

  公开号：EP1864986A1

  公开（公告）日：2007-12-12

  A pyrazolopyrimidine derivative represented by formula (1) and pharmaceutically acceptable salt thereof exhibit excellent inhibitory activity against MAPKAP-K2. Accordingly, medicines containing this compound as an active ingredient are expected to be effective for treating diseases mediated by MAPKAP-K2 such as, for example, inflammatory disorder, autoimmune diseases, destructive osteopathy, cancer and/or tumor growth.

  由式（1）代表的吡唑嘧啶衍生物及其药学上可接受的盐对 MAPKAP-K2 具有极佳的抑制活性。因此，含有这种化合物作为活性成分的药物有望有效治疗由 MAPKAP-K2 介导的疾病，例如炎症性疾病、自身免疫性疾病、破坏性骨病、癌症和/或肿瘤生长。
• US7473694B2
  申请人：——

  公开号：US7473694B2

  公开（公告）日：2009-01-06
• US8895580B2
  申请人：——

  公开号：US8895580B2

  公开（公告）日：2014-11-25